Please login to the form below

Not currently logged in
Email:
Password:

Topas Therapeutics appoints chief development officer and chief medical officer

Rupert Sandbrink joins from Forward Pharma

Topas Therapeutics has appointed Rupert Sandbrink as its new chief development officer and chief medical officer, a role that will see him lead the German group’s development and regulatory affairs.

Forging a 20-year-career spanning clinical development, regulatory and medical affairs and pharmacovigilance business, Dr Sandbrink’s expertise saw him most recently at Forward Pharma, where he served as executive vice president, multiple sclerosis/neurology and immunology.

Prior to that, he held several roles at Bayer, including vice president, head of experimental medicine of women’s health and common mechanism research.

Timm Jessen, chief executive officer, Topas, said: “Rupert has a long and successful track record of bringing drugs and biologics through clinical development and regulatory approval.

“He brings the critical expertise and experience that will help us immensely as we advance and prepare to enter our first program into the clinic. I am very excited to have him join the Topas team.”

At Topas, Dr. Sandbrink will guide projects into the clinic, design and execute clinical development programs and trials and lead the interactions with regulatory authorities.

3rd November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics